Last reviewed · How we verify
Dipeptidyl-Peptidase IV Inhibitors
Dipeptidyl-peptidase IV (DPP-4) inhibitors block the enzyme that degrades incretin hormones, thereby increasing insulin secretion and reducing glucagon in response to meals.
Dipeptidyl-peptidase IV (DPP-4) inhibitors block the enzyme that degrades incretin hormones, thereby increasing insulin secretion and reducing glucagon in response to meals. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Dipeptidyl-Peptidase IV Inhibitors |
|---|---|
| Also known as | linagliptin, DPP4 inhibitors |
| Sponsor | National University of Malaysia |
| Drug class | DPP-4 inhibitor |
| Target | Dipeptidyl peptidase IV (DPP-4) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
DPP-4 inhibitors work by inhibiting the enzyme dipeptidyl peptidase IV, which normally breaks down GLP-1 and GIP (glucose-dependent insulinotropic peptide). By preventing this degradation, these drugs prolong the action of endogenous incretin hormones, leading to glucose-dependent stimulation of insulin secretion and suppression of glucagon secretion, resulting in improved glycemic control.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Nasopharyngitis
- Headache
- Upper respiratory tract infection
- Hypoglycemia
Key clinical trials
- Effects of Cofrogliptin on Beta-Cell Function in LADA Patients (NA)
- A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy (PHASE4)
- Early Add-On Combination of GLP-1 Receptor Agonist and SGLT2 Inhibitor in People With Cardiovascular-Kidney-Metabolic Stage 2-3
- Observational Study of Triple Combination Therapy of Zemidapa Tab. and Metformin in Type 2 Diabetes Mellitus Patients
- Dose Optimization of Sitagliptin and Duloxetine in Diabetic Cirrhosis (PHASE4)
- Comparative Study Between (SGLT-2i) and (DPP-4i) in the Prevention of DIC (PHASE4)
- Oral Anti Diabetic Agents in the Hospital (PHASE4)
- Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: